tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['ca,022,i', 'tremelimumab', 'ts,perio,1', 'ev 202', 'aster,70', 'rova,(-approval),(-microvascular)', 'ca,022,1', 'durva', 'ts,perio,i', 'pone ', 'hcc', 'cv,202,103', 'sorafenib', 'himalaya']
4-years os update from himalaya ph-3 trial in unresectable hepatocellular carcinoma. stride regimen (tremelimumab + durvalumab) maintains significant long-term os benefit vs sorafenib. at 4 years, 1/4 of the patients in the stride arm remained alive. very good results! #wcgic2023 
MD de la UN. Especialista en medicina interna, docencia y oncología.